HepatologyNews.net

Hepatology Xagena

Xagena Mappa
Medical Meeting
Mediexplorer.it
XagenaNewsletter

The first prospective, longitudinal study investigating treatment of chronic hepatitis C with direct-acting antivirals finds that the treatment is associated with reduced risk of mortality and liver c ...


In the REACH-2 trial, Ramucirumab ( Cyramza ) has shown a statistically significant benefit in the primary endpoint of overall survival ( OS ) and in the secondary endpoint of progression-free surviva ...


Results from the largest study of hepatitis B and C and HIV infection prevalence in cancer patients show an alarmingly high rate of undiagnosed acute and chronic hepatitis B and C. Hepatitis B and C ...


Data are sparse on treatment of chronic hepatitis C virus ( HCV ) in cancer patients. Researchers have evaluated the efficacy and safety of Sofosbuvir-based therapy in cancer patients. Patients tr ...


The findings from a retrospective database analysis of patients with chronic hepatitis C virus ( HCV ) genotype ( GT ) 1 or 4 infection who have chronic kidney disease ( CKD ) and were treated with Ze ...


Although direct-acting antiviral ( DAA ) therapies for chronic hepatitis C virus ( HCV ) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, pote ...


Detailed results from an open-label phase 2 trial evaluating the investigational apoptosis signal-regulating kinase 1 ( ASK1 ) inhibitor Selonsertib ( formerly GS-4997 ) alone or in combination with t ...


Real-world effectiveness data are needed to inform hepatitis C virus ( HCV ) treatment decisions. The uptake of Ledipasvir and Sofosbuvir ( LDV/SOF; Harvoni ) regimens across health care settings has ...


Detailed 48-week results from two large phase 3 clinical trials ( Studies 108 and 110 ) evaluating once-daily Tenofovir alafenamide ( TAF ) 25 mg in treatment-naïve and treatment-experienced adults wi ...


Data has demonstrated that choosing a different combination of direct-acting antiviral ( DAA ) treatment for hepatitis C can eradicate the virus at four weeks in patients who had already failed on pre ...


A pilot study found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a short-duration of six weeks had undetectable HCV after a 12 week follow-up. The ...


New data has confirmed that a novel first-in-class treatment for hepatitis B, called NVR 3-778, is well-tolerated and can reduce levels of the virus’ genetic material in the body when combined with Pe ...


A hepatitis C ( HCV ) drug currently under investigation, ABT-493 and ABT-530, which is an all-oral once-daily antiviral treatment, helped HCV genotype 3 patients with heavily scarred livers and no pr ...


Interim results from one of the ongoing phase II studies of RG-101 for the treatment of hepatitis C virus infection ( HCV ) were announced. The study was designed to evaluate a shortened, 4-week tr ...


A study has evaluated the clinical outcomes of Telaprevir- or Simeprevir-based triple therapy for recurrent hepatitis C after living donor liver transplantation. Twenty-six patients received antiv ...